Avon's Breast Cancer Crusade to Offer 'Pink Ribbon' Pens

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 9
Volume 4
Issue 9

NEW YORK--Avon's Breast Cancer Awareness Crusade, which has raised $10 million through the sales of its $2 pink ribbon pin, has now introduced a pink-enameled ballpoint pen. The new pen, which bears the ribbon motif on its clip, will be available in October, 1995, at a cost of $3.

NEW YORK--Avon's Breast Cancer Awareness Crusade, which has raised$10 million through the sales of its $2 pink ribbon pin, has nowintroduced a pink-enameled ballpoint pen. The new pen, which bearsthe ribbon motif on its clip, will be available in October, 1995,at a cost of $3.

The pink ribbon has been selected by the breast cancer communityas the international symbol of hope and support for those affectedby breast cancer.

Proceeds from pen sales, as with ongoing sales of the pink ribbonpin, will go toward supporting community-based programs acrossthe country. These programs are dedicated to increasing awarenessof breast cancer and improving access to early detection services,especially for lower income, minority, and older women, and otherswho are medically underserved.

Woman-to-Woman Effort

Avon's Breast Cancer Awareness crusade has been working sinceOctober, 1993, to educate women about breast health. The crusadehas funded more than 125 community programs across the UnitedStates. In addition, Avon representatives have distributed 32million educational brochures in a woman-to-woman outreach effort.

Early on, Avon developed an innovative public/private/nonprofitpartnership with the YWCA of the USA, Centers for Disease Controland Prevention (CDC), National Alliance of Breast Cancer Organizations(NABCO), and National Cancer Institute, with the goal of improvingwomen's access to breast cancer services.

For information about the crusade and how to purchase the pinkribbon pen, call 1-800-FOR-AVON for the name of a neighborhoodAvon representative.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content